Acadia Pharmaceuticals Inc (ACAD): who owns it and who trades it
As of Nov 16, 2026, ACAD insiders reported 24 open-market sales worth $2.8M and no purchases in the last 12 months, with 32% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark C. Schneyer (CFO), with $1.2M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Acadia Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ACAD
350 funds and institutions reported ACAD shares worth $4.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 25.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 42.91M | 25.06% | $1.1B | No change |
| BlackRock, Inc. | 22.52M | 13.15% | $570M | +4% |
| State Street Corp | 9.08M | 5.30% | $230M | +9% |
| Vanguard Portfolio Management LLC | 8.84M | 5.16% | $224M | +2% |
| Rtw Investments, LP | 7.14M | 4.17% | $181M | No change |
| Vanguard Capital Management LLC | 5.76M | 3.37% | $146M | +2% |
| Dimensional Fund Advisors LP | 3.69M | 2.16% | $93.5M | +17% |
| California State Teachers Retirement System | 3.39M | 1.98% | $134M | +2352% |
| Geode Capital Management, LLC | 3.36M | 1.96% | $85M | -3% |
| Palo Alto Investors LP | 2.86M | 1.67% | $72.5M | -0% |
| Goldman Sachs Group Inc | 2.58M | 1.51% | $65.3M | +66% |
| Qube Research & Technologies Ltd | 2.45M | 1.43% | $61.9M | +157% |
| Point72 Asset Management, L.P. | 2.43M | 1.42% | $61.6M | -6% |
| Citadel Advisors LLC | 2.18M | 1.27% | $55.2M | +250% |
| Pictet Asset Management Holding SA | 1.98M | 1.16% | $50.1M | -2% |
| Arrowstreet Capital, Limited Partnership | 1.97M | 1.15% | $49.8M | +25% |
| Marshall Wace, LLP | 1.76M | 1.03% | $44.7M | – |
| D. E. Shaw & Co., Inc. | 1.70M | 0.99% | $43M | +133% |
| Braidwell LP | 1.65M | 0.96% | $41.7M | -33% |
| Norges Bank | 1.62M | 0.95% | $41.1M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ACAD insiders reported $0 of open-market purchases and $2.8M of sales. 32% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Mark C. Schneyer | CFO | Sale | 3,321 | $20.88 | $69.3K | Form 4 |
| Aug 6, 2026 | Mark C. Schneyer | CFO | Sale plan | 5,000 | $29.00 | $145K | Form 4 |
| Aug 6, 2026 | Mark C. Schneyer | CFO | Sale plan | 9,292 | $29.34 | $273K | Form 4 |
| Aug 5, 2026 | Mark C. Schneyer | CFO | Sale plan | 5,849 | $29.00 | $170K | Form 4 |
| Jul 30, 2026 | Elizabeth H.Z. Thompson | Vice president | Sale | 50 | $26.17 | $1.3K | Form 4 |
| Jul 30, 2026 | Elizabeth H.Z. Thompson | Vice president | Sale | 16,508 | $26.13 | $431K | Form 4 |
| Jun 26, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale plan | 11,421 | $26.08 | $298K | Form 4 |
| May 26, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 5,401 | $21.18 | $114K | Form 4 |
| May 4, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 1,332 | $21.79 | $29K | Form 4 |
| May 4, 2026 | Mark C. Schneyer | CFO | Sale | 3,506 | $21.79 | $76.4K | Form 4 |
| Apr 7, 2026 | Mark C. Schneyer | CFO | Sale | 2,709 | $22.20 | $60.1K | Form 4 |
| Apr 7, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 1,030 | $22.20 | $22.9K | Form 4 |
| Mar 26, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 1,097 | $21.65 | $23.8K | Form 4 |
| Mar 26, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 12 | $21.73 | $261 | Form 4 |
| Mar 26, 2026 | Mark C. Schneyer | CFO | Sale | 3,171 | $21.65 | $68.7K | Form 4 |
| Mar 26, 2026 | Mark C. Schneyer | CFO | Sale | 37 | $21.72 | $804 | Form 4 |
| Mar 25, 2026 | Adams Catherine Owen | CEO | Sale | 11,641 | $21.47 | $250K | Form 4 |
| Mar 25, 2026 | Jennifer J Rhodes | Vice president | Sale | 3,844 | $21.47 | $82.5K | Form 4 |
| Mar 25, 2026 | Elizabeth H.Z. Thompson | Vice president | Sale | 3,435 | $21.47 | $73.7K | Form 4 |
| Mar 25, 2026 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 833 | $21.47 | $17.9K | Form 4 |
| Mar 25, 2026 | Mark C. Schneyer | CFO | Sale | 4,177 | $21.47 | $89.7K | Form 4 |
| Feb 9, 2026 | Jennifer J Rhodes | Vice president | Sale | 6,950 | $23.38 | $162K | Form 4 |
| Nov 18, 2025 | Mark C. Schneyer | CFO | Sale | 10,262 | $23.69 | $243K | Form 4 |
| Nov 18, 2025 | James Kihara | PRINCIPAL ACCOUNTING OFF | Sale | 4,084 | $23.69 | $96.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | – | $1.2M | Oct 30, 2026 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | – | $603K | Jun 26, 2026 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | – | $506K | Jul 30, 2026 |
| Adams Catherine Owen | Chief Executive Officer, Director | – | $250K | Mar 25, 2026 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | – | $245K | Mar 25, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ACAD short interest
Low short interest. 4.8% of ACAD shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went down 27%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.32M ACAD shares were sold short, 4.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.40M shares, buying them all back would take about 5.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.32M | 4.81% | -9% | 1.40M | 5.9 |
| Oct 15, 2026 | 9.09M | 5.28% | +10% | 1.99M | 4.6 |
| Sep 30, 2026 | 8.28M | 4.80% | -14% | 2.83M | 2.9 |
| Sep 15, 2026 | 9.67M | 5.61% | -1% | 1.34M | 7.2 |
| Aug 31, 2026 | 9.74M | 5.65% | +3% | 1.40M | 6.9 |
| Aug 14, 2026 | 9.48M | 5.50% | -12% | 2.09M | 4.5 |
| Jul 31, 2026 | 10.81M | 6.27% | -2% | 1.36M | 8.0 |
| Jul 15, 2026 | 11.03M | 6.44% | +1% | 1.45M | 7.6 |
| Jun 30, 2026 | 10.95M | 6.40% | -7% | 2.31M | 4.8 |
| Jun 15, 2026 | 11.81M | 6.90% | +0% | 1.05M | 11.3 |
| May 29, 2026 | 11.75M | 6.86% | +3% | 1.45M | 8.1 |
| May 15, 2026 | 11.42M | 6.67% | +2% | 1.95M | 5.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Acadia Pharmaceuticals company events
Acadia Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 23, 2026LeadershipDeparture Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Sep 24, 2026AnnouncementThe Company announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with ADP. For the primary endpoint of change from baseline in the Scale for the… Filing
- Sep 11, 2026AnnouncementThe United States District Court for the Southern District of California preliminarily approved the settlement of the stockholder derivative action captioned Kanner et al. v. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- May 29, 2026LeadershipAcadia Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 6, 2026ResultsReleased financial results. Filing
- May 1, 2026LeadershipDeparture Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Mar 5, 2026LeadershipThe board of directors of Acadia Pharmaceuticals Inc., upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jonathan M. Poole to the Board to fill a vacancy and as a member of the Audit Committee of the Board, effective immediately. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 13, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Acadia Pharmaceuticals financials
Famous investors that hold ACAD
7 of the 50 well-known investors we track reported holding ACAD in their latest 13F filing. The largest position is Ken Griffin's, worth $38.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.93M | $38.9M | 0.0% | -11% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.14M | $22.9M | 0.0% | -53% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.11M | $22.3M | 0.0% | -14% |
| Israel Englander · Millennium Management | Q3 2026 | 795,315 | $16M | 0.0% | +35% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 711,352 | $14.3M | 0.0% | +2% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 105,337 | $2.1M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 48,861 | $985K | 0.0% | -3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ACAD in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
Questions about Acadia Pharmaceuticals Inc (ACAD) stock
Who owns the most ACAD stock?
The largest reported owner of Acadia Pharmaceuticals Inc (ACAD) is Baker Bros. Advisors LP, with 25.1% of the company. In total, 350 funds and institutions reported holding ACAD at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ACAD insiders buying or selling?
In the last 12 months, ACAD insiders reported no open-market purchases and 24 sales worth $2.8M. The latest trade was on Oct 30, 2026. See every trade.
What is the short interest in ACAD?
As of Oct 30, 2026, 8.32M ACAD shares were sold short, 4.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.40M shares, buying them all back would take about 5.9 trading days (days to cover). See the history.
Which famous investors hold ACAD?
7 of the 50 well-known investors we track reported ACAD in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $38.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.